Search Results
Your search for ,loW matches 7101 pages
Showing 1351 - 1400Expert Point of View: Joelle Fathi, DNP, RN, ARNP, CTTS, FAAN
An expert on the panel discussion of lung cancer screening from the Quantitative Imaging Workshop XIX, Joelle Fathi, DNP, RN, ARNP, CTTS, FAAN, Chief Healthcare Delivery Officer for the GO2 Foundation for Lung Cancer, called the lung cancer screening study a powerful reminder of the reality on the...
Lung Cancer Screening Perceptions of Patients and Clinicians: The Power of Shared Decision-Making
Despite the benefits of lung cancer screening, including the high cure rate when found by screening compared to being discovered based on symptoms, the uptake of this technique among those who are eligible and where the screening is fully covered by insurance remains dismally low, on the order of...
How ASCO and the Oncology Community Came Together to Discuss Progress in Global Cancer Control and the Challenges Ahead
After a 4-year in-person hiatus because of the COVID-19 global pandemic, the World Cancer Congress, hosted by the Union for International Cancer Control (UICC), held its first hybrid in-person and virtual meeting in October in Geneva. The conference brought together more than 2,000 attendees from...
Changing Landscape in the Management of High-Risk Lesions for Breast Cancer
As the population of women at increased risk for breast cancer grows, with an estimated 140,000 high-risk lesions diagnosed each year, “the landscape for surgical excision of high-risk lesions continues to evolve,” Melissa Pilewskie, MD, reported at the 2022 Lynn Sage Breast Cancer Symposium in...
Study Finds Microbiome-Derived Vaccine Plus Nivolumab and Bevacizumab May Improve Outcomes in Recurrent Glioblastoma
A microbiome-derived therapeutic vaccine (EO2401) has demonstrated immune responses and anticancer activity in combination with nivolumab and bevacizumab in patients with recurrent glioblastoma, one of the most difficult-to-treat cancers, according to data presented at the 2022 Society for...
Study Finds Medicaid Expansion May Improve Survival Outcomes for Young Adult Patients With Cancer
Researchers have discovered that expanded Medicaid coverage under the Affordable Care Act may lead to better survival outcomes for young adult patients aged 18 to 39 years who have been newly diagnosed with cancer—particularly among those who identify as Hispanic or non-Hispanic Black—according to...
Risk Model for Predicting the Development of Prostate Cancer
In a study reported in the Journal of Clinical Oncology, Nyberg et al developed the risk model CanRisk-Prostate for predicting the development of prostate cancer based on age, detailed cancer family history, moderate- to high-risk pathogenic variants, and a polygenic score for common low-risk...
A Serendipitous Ride Along a Highway May Have Saved My Life
In 2017, I noticed a roadside billboard touting the benefits of low-dose computed tomography (CT) imaging for lung cancer screening. The message probably saved my life. The public service campaign, called Saved by the Scan from the American Lung Association, included an Internet address where I...
Risk of Adverse Side Effects From Cancer Immunotherapy May Be Higher in Patients With Certain Inherited Genetic Variations
Even as they’ve revolutionized cancer treatment, immune checkpoint inhibitors have been shown to produce a range of adverse immune-related side effects. Researchers have now identified inherited genetic variations that may place patients at high risk for complications when undergoing treatment with ...
Understanding the Health Provisions in the Inflation Reduction Act and Their Implications for Oncology Care
The Inflation Reduction Act of 2022, signed into law on August 16, 2022, contains several important provisions regarding health care and drug pricing.1 In this article, I provide an overview of the legislation’s implications for oncology care, focusing on its provisions concerning drug price...
Chemotherapy Dose Intensity and Survival in Older Women With Early-Stage Breast Cancer: Analysis From the HOPE Trial
In an analysis from the HOPE trial reported in the Journal of Clinical Oncology, Mina S. Sedrak, MD, MS, and colleagues found that approximately one-fifth of older women with early-stage breast cancer received a relative dose intensity (RDI) of neoadjuvant/adjuvant chemotherapy that was below...
Prostate Cancer Screening With MRI-Targeted vs MRI-Targeted and Systemic Biopsy
In a Swedish study (GÖTEBORG-2) reported in The New England Journal of Medicine, Hugosson et al found that magnetic resonance imaging (MRI)-targeted prostate biopsy was associated with a lower risk of overdiagnosis of clinically insignificant prostate cancer compared with MRI-targeted and...
Brain Cancer After CT Scans in Children and Young Adults
In a European cohort study (EPI-CT) reported in The Lancet Oncology, Hauptmann et al found an increased risk of brain cancer with increasing brain radiation dose among children and young adults who had undergone computed tomography (CT) scans. Study Details The study used pooled data from nine...
Sean Khozin, MD, MPH, on Randomized Trials vs Real-World Evidence in Patients With Advanced Cancer
Sean Khozin, MD, MPH, of the Massachusetts Institute of Technology, discusses the “external validity deficits” of randomized clinical trials, which still involve only about 5% of adults with cancer, who may differ in important ways from real-world populations. Dr. Khozin describes the reasons for...
Chemotherapy-Free Regimen of Ponatinib and Blinatumomab May Be Effective for Patients With Newly Diagnosed Philadelphia Chromosome–Positive ALL
A new phase II trial demonstrated that the chemotherapy-free regimen of ponatinib and blinatumomab may have achieved high response rates and reduced the need for an allogeneic stem cell transplant for patients with recently diagnosed Philadelphia chromosome–positive (Ph+) acute lymphoblastic...
New Clinical Tool for Clonal Hematopoiesis May Identify Patients at High Risk for Hematologic Cancer
A new clinical tool may pinpoint which patients with clonal hematopoiesis are at highest risk for cancer progression, according to new findings presented by Weeks et al at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 926). Background Clonal hematopoiesis—a...
Three-Drug Combination Therapy May Be Effective in Patients With High-Risk CLL
A three-drug combination that showed success at sending patients with chronic lymphocytic leukemia (CLL) into deep remissions in a clinical trial may be effective at treating patients with high-risk types of the disease, according to new findings presented by Ryan et al at the 2022 American Society ...
TAILORx Update: 12-Year Recurrence and Survival Outcomes for Patients With Early-Stage Breast Cancer
Long-term recurrence and survival data are now available from the groundbreaking TAILORx trial. With 12 years of follow-up, the updated analysis—reported by Sparano et al at the San Antonio Breast Cancer Symposium (SABCS) 2022 (Abstract GS1-05)—confirms the original findings that chemotherapy may...
Global Study Uncovers Regional Differences in the Use of Curative Transplants for Patients With AML
The use of stem cell transplantation for acute myeloid leukemia increased by about 55% worldwide from 2009 to 2016, according to new findings presented by Niederweiser et al at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 3638). Although the largest...
Identifying Which Patients Receive the Most Specialized Types of Stem Cell Transplant Requiring the Highest Level of Care
Patients of non-European ancestry and especially those of low socioeconomic status are more likely to receive the most specialized types of allogeneic stem cell transplantation that require the highest level of care, according to new findings presented by Fingrut et al at the 2022 American Society...
Prudence A. Francis, MD, on Premenopausal ER-Positive Breast Cancer: Past, Present, and Future
Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre, discusses an update of the SOFT trial, which showed that adding ovarian function suppression (OFS) to adjuvant tamoxifen for premenopausal women with estrogen receptor (ER)-positive breast cancer reduces the risk of recurrence. OFS...
Efficacy of Sacituzumab Govitecan in TROPiCS-02 Trial Not Dependent on Trop-2 Expression
The latest analysis of the TROPiCS-02 breast cancer trial shows that sacituzumab govitecan-hziy is effective in patients with a wide range of Trop-2 expression levels. The findings were reported at the 2022 San Antonio Breast Cancer Symposium by Hope S. Rugo, MD, FASCO, Professor of Medicine and...
Andrea De Censi, MD, on Noninvasive Breast Cancer: 10-Year Results on Low-Dose Tamoxifen
Andrea De Censi, MD, PhD, of Italy’s E.O. Ospedali Galliera, discusses phase III findings showing that low-dose tamoxifen (so-called babytam) given for 3 years still significantly prevents recurrences from noninvasive breast cancer after a median of 7 years from treatment cessation. Babytam at 5...
Ann H. Partridge, MD, MPH, on Interrupting Breast Cancer Treatment to Attempt Pregnancy
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the POSITIVE trial, which showed that a temporary interruption of endocrine therapy in women with hormone-responsive breast cancer in order to attempt pregnancy, does not affect short-term disease outcomes. The study ...
Commonly Prescribed Restrictive Diet May Be Unnecessary Before Autologous Stem Cell Transplantation
People undergoing a stem cell transplant for cancer do not derive any benefit from a restrictive diet that is commonly prescribed to prevent infections, according to a new trial presented by Stella et al at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 169)....
Per Karlsson, MD, PhD: New Data on Breast-Conserving Surgery, With or Without Radiotherapy
Per Karlsson, MD, PhD, of Sweden’s University of Gothenburg and the Sahlgrenska Comprehensive Cancer Center, discusses results from the POLAR study, which was a meta-analysis of three clinical trials of breast-conserving surgery with or without radiotherapy. POLAR is the first genomic classifier...
Elacestrant vs Endocrine Monotherapy in Advanced Breast Cancer: Phase III EMERALD Trial
Elacestrant—an investigational oral selective estrogen receptor degrader (SERD)—achieved longer progression-free survival vs standard-of-care endocrine monotherapy as second- or third-line therapy in patients with estrogen receptor (ER)-positive, HER2-negative, advanced or metastatic breast cancer...
Genetic Profiling May Identify Patients With Breast Cancer Who Can Safely Omit Radiation Therapy After Breast-Conserving Surgery
Patients with invasive breast cancer who had low scores on an investigational gene molecular signature had similar rates of local recurrence independent of whether they received adjuvant radiation therapy after breast-conserving surgery, according to findings presented by Karlsson et al at the 2022 ...
2022 Society for Integrative Oncology Annual International Conference
Guest Editor’s Note: In October, the Society for Integrative Oncology (SIO) held its 2022 Annual International Conference in a hybrid format (virtual and in Scottsdale, Arizona). It was centered on the basic science, education and training, and implementation of integrative oncology in diverse...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Bolivia
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Bolivia. The aim of this special feature is to highlight the global cancer burden for various countries of the...
The Effect of the Reversal of Roe v Wade on Care of Pregnant Women With Cancer
The repercussions from the decision by the U.S. Supreme Court on June 24, 2022, to overturn Roe v Wade, effectively ending a nearly 50-year federal constitutional right to an abortion and allowing instead states to determine abortion access, are starting to be felt in the cancer care community. The ...
Dabrafenib in Combination With Trametinib for Unresectable or Metastatic Solid Tumors With BRAF V600E Mutation
On June 22, 2022, dabrafenib in combination with trametinib was granted accelerated approval for treatment of adult and pediatric patients (aged 6 and older) with unresectable or metastatic solid tumors with BRAF V600E mutation whose disease progressed following prior treatment and who have no...
Circulating Tumor Cell Count–Driven Treatment Decisions May Improve Long-Term Outcomes for Patients With Metastatic Breast Cancer
The use of circulating tumor cell counts to guide the choice between chemotherapy and endocrine therapy as first-line treatment for patients with metastatic, estrogen receptor–positive, HER2-negative breast cancer provided overall survival benefits compared with physician’s choice of treatment,...
Adding Capivasertib to Fulvestrant May Improve Progression-Free Survival in Patients With Advanced Hormone Receptor–Positive Breast Cancer
In patients with hormone receptor–positive, HER2-negative breast cancer who are resistant to aromatase inhibitors, the addition of the investigational AKT inhibitor capivasertib to fulvestrant doubled the median progression-free survival compared with placebo plus fulvestrant, according to results...
How Low-Dose Oral Minoxidil Is Providing Hope for Patients With Later-Stage Alopecia
Chemotherapy-induced hair loss affects 65% of patients with cancer,1 and the psychosocial impact on these patients can be profound; it may include anxiety, depression, a negative body image, lowered self-esteem, and a reduced sense of well-being.2 In some instances, the fear of hair loss from...
Sara A. Hurvitz, MD: New Findings on Neoadjuvant Trastuzumab Deruxtecan and Anastrozole in Early-Stage Breast Cancer
Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses phase II results from the TRIO-US B-12 TALENT study, which showed that patients with localized, hormone receptor–positive, HER2-low breast cancer who are treated with fam-trastuzumab...
Study Finds Patritumab Deruxtecan Active in HER3-Expressing Metastatic Breast Cancer
The HER3-directed antibody-drug conjugate patritumab deruxtecan (HER3-DXd) showed activity in patients with heavily pretreated HER3-expressing metastatic breast cancer in a phase I/II study. Ian E. Krop, MD, PhD, Associate Director, Yale Cancer Center, New Haven, Connecticut, presented these...
Capturing Tumor Evolution With Serial Biopsies May Guide Treatment Changes to Benefit Patients With Breast Cancer
Molecular testing and genomic testing are now considered standard of care in breast cancer, guiding treatment decisions in early breast cancer and targeted therapies in the metastatic setting. “But tumors evolve,” Virginia Kaklamani, MD, DSc, reminded participants at the 2022 Lynn Sage Breast...
Ruth O’Regan, MD, on Evaluation of the Breast Cancer Index in Early-Stage Breast Cancer
Ruth O’Regan, MD, of the University of Rochester Medical Center, discusses the Breast Cancer Index (BCI), a genomic assay that can assess the risk of late distant recurrence (5–10 years after diagnosis) of hormone receptor–positive, early-stage breast cancer. Among premenopausal women with this...
Neoadjuvant T-DXd Shows Clinical Activity in Patients With HER2-Low Breast Cancer
Patients with localized, hormone receptor (HR)-positive, HER2-low breast cancer treated with fam-trastuzumab deruxtecan-nxki (T-DXd) in the neoadjuvant setting had an overall response rate of 75% without combining the agent with anastrozole and 63% in combination with anastrozole, according to...
Cancer Drugs and Price Controls: Is It Time?
According to a recent article published in Cancer Epidemiology, Biomarkers & Prevention, cancer care in the United States exceeded $208 billion in 2020 and is expected to surpass $240 billion by 2030.1 These estimates are driven largely by a growing and aging population. The expenditures...
PCS5 Trial: 5 Weeks of Radiation Therapy May Be Equivalent to 8 Weeks in High-Risk Prostate Cancer
According to the results of the phase III randomized Prostate Cancer Study 5 (PCS5), a noninferior trial, 5 weeks of radiation therapy may be equivalent to 8 weeks for men with high-risk prostate cancer on androgen-deprivation therapy. These findings were presented at the 2022 American Society for...
Breast Implants After Mastectomy Associated With Very Low Risk of ALCL
The incidence of anaplastic large cell lymphoma (ALCL) has surged in recent years—possibly because of the growing use of textured breast implants. Considering this trend, some patients with breast cancer who undergo mastectomy may wonder if the benefits of getting reconstructive implants are worth...
Machine Learning–Based Scoring of TILs and Outcomes With Immunotherapy in Patients With NSCLC
In a retrospective study reported in JAMA Oncology, Rakaee et al found that tumor-infiltrating lymphocyte (TIL) levels ascertained via machine learning–based scoring on standard histologic images were associated with response in patients receiving immune checkpoint inhibitor therapy for non–small...
Study Finds Racial Disparity in Prometastatic Tumor Microenvironment Among Patients With Residual Breast Cancer After Neoadjuvant Chemotherapy
Residual tumors from Black patients with estrogen receptor–positive/HER2-negative primary breast cancer treated with neoadjuvant chemotherapy had a higher risk score associated with a biomarker of distant metastatic recurrence compared with tumors from White patients, according to new findings...
Genomic Assay May Predict Long-Term Prognosis in Premenopausal Patients With Hormone Receptor–Positive Early-Stage Breast Cancer
Among premenopausal patients with hormone receptor–positive, early-stage breast cancer enrolled in the SOFT trial, those with a high score on the Breast Cancer Index genomic assay had an increased risk of distant recurrence—and those with a low score on the Breast Cancer Index may have benefited...
Black Patients With Breast Cancer May Have Worse Outcomes Than Other Patients Despite Similar Genetic Recurrence Scores
Non-Hispanic Black patients with lymph node–positive, hormone receptor (HR)–positive/HER2-negative breast cancer experienced worse outcomes compared with the outcomes of non-Hispanic White, Asian, and Hispanic patients—despite similar 21-gene recurrence scores—according to new findings presented by ...
Lung Cancer Screening May Increase Long-Term Survival Rate
Diagnosing early-stage lung cancer using low-dose computed tomography (CT) screenings may improve patients’ long-term survival rate, according to long-term findings from the International Early Lung Cancer Action Program presented at the Radiological Society of North America (RSNA) 2022 Annual...
Study Finds Americans Have a Low Awareness of the Link Between Alcohol Use and Increased Cancer Risk
Research shows that all beverage types containing ethanol, including wine, beer, and hard liquor, increase cancer risk, and that the risk increases with higher alcohol consumption. Even light drinking—no more than one drink per day—increases the risk for some cancers, including esophageal and...
Novel DELFI AI Blood Test May Aid in Detecting Hepatocellular Carcinoma
A novel artificial intelligence (AI) blood testing technology—known as DELFI (DNA evaluation of fragments for early interception)—may successfully detect more than 80% of hepatocellular carcinomas, according to a new study published by Foda et al in Cancer Discovery. The findings were also...
